|
| Product | Application | Host plant | Status | Company |
|
| Recombinant human intrinsic factor | Vitamin B12 deficiency | Arabidopsis thaliana | Phase II completed 2006 | University in Aarhus, Denmark |
|
| Recombinant human lactoferrin | anti-inflammatory conditions in HIV patients | rice (Oryza sativa) | Phase I and Phase II, completed 2006, under Phase III | Jason Baker (MMRF), USA
Ventria Bioscience, USA |
|
Locteron™,
a controlled release interferon | Hepatitis B and Hepatitis C | duckweed (Lemna minor) | Phase I and II, completed 2009, under Phase III | Biolex Therapeutics, USA |
|
| P2G12 antibody | HIV | tobacco (Nicotiana tabacum) | Phase I completed 2011 | University of Surrey, Guildford, UK |
|
| HIV antibody | HIV | Tobacco (N. tabacum) | Phase I | Fraunhofer IME |
|
Insulin
(SBS-1000) | diabetes | safflower (Carthamus tinctorius) | Phase II, Phase III completed | SemBioSys |
|
| Taliglucerase alga | Gaucher disease | carrot (Daucus carota) suspension culture (Elelyso™) | Phase III completed 2012, approved by FDA
2012 | Protalix Biotherapeutics Karmiel, Israel |
|
| HAI-05 | H5N1 vaccine | tobacco (N. tabacum) | Phase I, 2011 | Center for Molecular Biotechnology, Plymouth, MI, USA |
|
Recombinant interferon
(IFN-α2b) | antiviral treatment | duckweed (L. minor) | Phase II | Biolex Therapeutics, USA |
|
| HAI-05 | H5N1 vaccine | tobacco (N. tabacum) | Phase II, 2012 | Medicago Inc., USA & Canada |
|
Human
α-galactosidase | Fabry disease | Moss (Physcomitrella patens) | Phase I | Greenovation Biotech GmbH, Germany |
|
| PRX-102 | Fabry disease | tobacco suspension culture | Phases I and II, 2014 | Protalix Biotherapeutics Karmiel, Israel |
|
| Vaccine recombinant protective antigen | Anthrax | tobacco (N. tabacum) | Phase I, 2014 | Center for Molecular Biotechnology, Plymouth, MI, USA |
|
| H5-VLP+GLA-AF vaccine | Influenza A subtype H5N1 infection | tobacco (N. tabacum) | Phase I completed, 2014 | Infectious Disease Research Institute, Seattle, WA, USA |
|
| Vaccine Pfs25 VLP | Malaria | tobacco (N. tabacum) | Phase I, 2015 | Center for Molecular Biotechnology, Plymouth, MI, USA |
|
| ZMApp | Ebola virus | tobacco (N. tabacum) | Phases I and II, 2015 | National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA |
|
CaroRx
(Anti-caries) | dental prophylaxis | tobacco (N. tabacum) | Discontinued, 2016. 2. 17; Approved as medical device | Planet Biotechnology |
|
Anti-west virus
mAb Hu-E16 | Anti-west virus | Nicotiana benthamiana | Phase II | MacroGenics, NIH |
|
Human Epidermal
growth factor | burns treatments | barley seed (Hordeum vulgare) | Commercialization | ORF, Sif Cosmetics |
|
| Human growth hormone | deficiency treatments | barley seed (H. vulgare) | Commercialization | ORF |
|
| single-chain Fv (scFv) epitopes | treatment of non-Hodgkin’s
lymphoma | N. benthamiana | Phase I | Large Scale Biology Corp., Vacaville, CA |
|
| VEN200 (albumin) | deficiency treatments | rice seed (O. sativa) | Phase II | Ventria Bioscience |
|
| RhinoRx™ | rhinovirus | tobacco (N. tabacum) | Phase II | Planet Biotechnology |
|
| Newcastle disease virus protein | poultry vaccine | plant cell cultures | USDA approved | Dow AgroSciences |
|
| Protein E envelop of Zika virus | Zika virus | N. benthamiana | Preclinical trials | Arizona State University, Tempe, AZ, USA |
|
